A Research Genetic sequencing laboratory
Signed in as:
filler@godaddy.com
A Research Genetic sequencing laboratory
Signed in as:
filler@godaddy.com
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.
This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.
This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.
This study seeks to determine whether the virus which causes COVID-19, SARS-CoV-2, is shed in the stools of patients who are infected.
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent infection with COVID-19. The study will last 24 weeks.
This Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection). The study will last 24 weeks.
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
(Myalgic Encephalomyelitis/
Chronic Fatigue Syndrome)
The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda
The terms REFLORALIZE™ and REFLORALIZATION™ were created by Sabine Hazan, MD, and are Trademarks, reference #19-38771
Copyright © ProgenaBiome™, LLC MMXIX -All Rights Reserved. 2019